SEOM clinical guideline for treatment of kidney cancer (2017)
Clin. transl. oncol. (Print)
; 20(1): 47-56, ene. 2018. tab
Article
in English
| IBECS
| ID: ibc-170467
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge (AU)
RESUMEN
No disponible
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
Type of study:
Controlled clinical trial
/
Etiology study
/
Practice guideline
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2018
Document type:
Article
Institution/Affiliation country:
Clinica Universidad de Navarra/Spain
/
Hospital Clínico/Spain
/
Hospital Universitari Mutua Terrassa/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario Ramón y Cajal/Spain
/
Hospital Universitario Son Espases/Spain
/
Institut Catala dOncologia/Spain
/
Parc Taulí Hospital Universitari/Spain
/
Reina Sofía Hospital/Spain
/
Vall dHebron University Hospital and Institute of Oncology/Spain